Description
Medpace is a midsize, clinical contract research organization (CRO) based in Cincinnati, Ohio. It provides services for Phase I-IV of drug and medical device development services including regulatory services and central laboratory services. The company started trading stock as a public firm in 2016.
History
Dr. August Troendle founded Medpace in Cincinnati, Ohio in 1992 as Medical Rearch Services. Dr. Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol.
With a team of industry physicians, Dr. Jonathan Issacsohn and Dr. Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. Another Medpace physician, the late Dr. David Orloff was regarded as an industry opinion leader in the study of metabolic diseases - most specifically diabetes and obesity. Dr. Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce.
Medpace completed construction on a new campus in 2012 in Madisonville, a village in the city of Cincinnati. This was a project completed in cooperation with Madisonville, the City of Cincinnati Department of Economic Development, and the State of Ohio. The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED certified campus.
Acquisitions
- 2007-Medpace acquires Monax in the Czech Republic
- 2009-Medpace acquires PharmaBrains AG in Switzerland
- 2010-Medpace acquires Symbios, a medical device consultancy in Minneapolis, MN
- 2010-Medpace acquires Medical Consulting Dr. Schlichtiger, GmbH, in Germany
- 2012-Medpace acquires MediTech BV, a medical device consultancy in the Netherlands.
